Correction
This article was originally published in The Tan Sheet
Executive Summary
Due to a transcription error in the June 21 story, "Perrigo Targets October For Quality System Corrections, FDA Re-inspection," we mistakenly paraphrased Perrigo Chief Financial Officer Judy Brown's comment on the firm's estimated costs for consultants. It should have read "several million dollars." "The Tan Sheet" regrets the error
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.